Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Verastem, Inc. (VSTM : NSDQ)

• Company Description    Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $6.69 Daily Weekly Monthly 20 Day Moving Average: 1,169,356 shares Shares Outstanding: 51.49 (millions) Market Capitalization: $344.47 (millions) Beta: 0.85 52 Week High: $13.52 52 Week Low: $2.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.70% 22.78% 12 Week 10.03% 18.25% Year To Date 29.40% 35.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 117 KENDRICK STREET SUITE 500 - NEEDHAM,MA 02494 USA ph: 781-292-4200 fax: - investors@verastem.com http://www.verastem.com

• General Corporate Information    Officers Daniel W. Paterson - President and Chief Executive Officer Matthew E. Ros - Chief Operating Officer Daniel Calkins - Chief Financial Officer Paul Bunn - Director Robert Gagnon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92337C203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/08/25 Share - Related Items Shares Outstanding: 51.49 Most Recent Split Date: 6.00 (0.08:1) Beta: 0.85 Market Capitalization: $344.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.75 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -30.39% vs. Previous Quarter: -121.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - -2,003.62 09/30/24 - -332.73 ROA 03/31/25 - - 12/31/24 - -114.29 09/30/24 - -73.97 Current Ratio 03/31/25 - - 12/31/24 - 3.07 09/30/24 - 3.23 Quick Ratio 03/31/25 - - 12/31/24 - 3.07 09/30/24 - 3.23 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - -1,304.52 09/30/24 - -934.54 Book Value 03/31/25 - - 12/31/24 - -0.65 09/30/24 - 0.27 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - - 09/30/24 - 2.77 Debt-to-Capital 03/31/25 - - 12/31/24 - - 09/30/24 - 48.75

Powered by Zacks Investment Research ©